Published in Retrovirology on August 17, 2010
Recombinant origin of the retrovirus XMRV. Science (2011) 3.54
Absence of XMRV retrovirus and other murine leukemia virus-related viruses in patients with chronic fatigue syndrome. J Virol (2011) 1.73
Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science (2011) 1.56
Serologic and PCR testing of persons with chronic fatigue syndrome in the United States shows no association with xenotropic or polytropic murine leukemia virus-related viruses. Retrovirology (2011) 1.42
The Blood Xenotropic Murine Leukemia Virus-Related Virus Scientific Research Working Group: mission, progress, and plans. Transfusion (2011) 1.41
PCR master mixes harbour murine DNA sequences. Caveat emptor! PLoS One (2011) 1.41
The mouse "xenotropic" gammaretroviruses and their XPR1 receptor. Retrovirology (2010) 1.35
In-depth investigation of archival and prospectively collected samples reveals no evidence for XMRV infection in prostate cancer. PLoS One (2012) 1.33
Infection, viral dissemination, and antibody responses of rhesus macaques exposed to the human gammaretrovirus XMRV. J Virol (2011) 1.28
No evidence for XMRV in German CFS and MS patients with fatigue despite the ability of the virus to infect human blood cells in vitro. PLoS One (2010) 1.25
No association of xenotropic murine leukemia virus-related virus with prostate cancer or chronic fatigue syndrome in Japan. Retrovirology (2011) 1.22
No association of xenotropic murine leukemia virus-related viruses with prostate cancer. PLoS One (2011) 1.19
No evidence of XMRV in prostate cancer cohorts in the Midwestern United States. Retrovirology (2011) 1.18
The xenotropic murine leukemia virus-related retrovirus debate continues at first international workshop. Retrovirology (2010) 0.98
Retracted Identification of XMRV infection-associated microRNAs in four cell types in culture. PLoS One (2012) 0.89
No evidence for xenotropic murine leukemia-related virus infection in Sweden using internally controlled multiepitope suspension array serology. Clin Vaccine Immunol (2012) 0.88
XMRV: usage of receptors and potential co-receptors. Virol J (2011) 0.88
Phylogeny-directed search for murine leukemia virus-like retroviruses in vertebrate genomes and in patients suffering from myalgic encephalomyelitis/chronic fatigue syndrome and prostate cancer. Adv Virol (2011) 0.83
Failure to Detect XMRV-Specific Antibodies in the Plasma of CFS Patients Using Highly Sensitive Chemiluminescence Immunoassays. Adv Virol (2011) 0.82
Development and application of a high-throughput microneutralization assay: lack of xenotropic murine leukemia virus-related virus and/or murine leukemia virus detection in blood donors. Transfusion (2012) 0.81
Antibody responses against xenotropic murine leukemia virus-related virus envelope in a murine model. PLoS One (2011) 0.80
Prevalence of XMRV nucleic acid and antibody in HIV-1-Infected men and in men at risk for HIV-1 Infection. Adv Virol (2011) 0.78
Absence of detectable XMRV and other MLV-related viruses in healthy blood donors in the United States. PLoS One (2011) 0.76
XMRV Discovery and Prostate Cancer-Related Research. Adv Virol (2011) 0.76
Cholesterol depletion inactivates XMRV and leads to viral envelope protein release from virions: evidence for role of cholesterol in XMRV infection. PLoS One (2012) 0.75
Testing strategies for detection of xenotropic murine leukemia virus-related virus infection. Adv Virol (2011) 0.75
Retracted Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science (2009) 10.76
Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog (2006) 10.08
Retracted XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci U S A (2009) 6.72
An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci U S A (2007) 4.77
Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS One (2010) 4.66
Retrovirus envelope domain at 1.7 angstrom resolution. Nat Struct Biol (1996) 4.49
Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol (2008) 4.25
Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology (2010) 4.18
Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients. Retrovirology (2009) 4.11
Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science (1985) 3.81
Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology (2010) 3.64
Serological markers in early stages of human immunodeficiency virus infection in haemophiliacs. Lancet (1986) 2.92
Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. J Virol (2008) 2.83
XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. Urology (2010) 2.55
The discovery of endogenous retroviruses. Retrovirology (2006) 2.18
Seven human immunodeficiency virus (HIV) antigen-antibody combination assays: evaluation of HIV seroconversion sensitivity and subtype detection. J Clin Microbiol (2001) 1.45
Evaluation of 14 commercial HIV-1/HIV-2 antibody assays using serum panels of different geographical origin and clinical stage including a unique seroconversion panel. J Virol Methods (1998) 1.39
Host range and cellular tropism of the human exogenous gammaretrovirus XMRV. Virology (2010) 1.38
Xenotropic murine leukemia virus-related virus establishes an efficient spreading infection and exhibits enhanced transcriptional activity in prostate carcinoma cells. J Virol (2009) 1.35
Infection, viral dissemination, and antibody responses of rhesus macaques exposed to the human gammaretrovirus XMRV. J Virol (2011) 1.28
Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. Proc Natl Acad Sci U S A (2010) 1.18
Characterization of the type and group specificities of the immune response in mice to murine leukemia viruses. J Virol (1976) 1.18
Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum Gene Ther (1990) 1.11
Natural immunity in mice to structural polypeptides of endogenous type C RNA viruses. J Virol (1976) 1.06
The prostate cancer-associated human retrovirus XMRV lacks direct transforming activity but can induce low rates of transformation in cultured cells. J Virol (2009) 1.02
Spectrum of natural antibodies against five HTLV-III antigens in infected individuals: correlation of antibody prevalence with clinical status. Blood (1987) 1.01
Detection of early human T-cell lymphotropic virus type I antibody patterns during seroconversion among transfusion recipients. Blood (1991) 0.98
Comparative evaluation of 14 immunoassays for detection of antibodies to the human T-lymphotropic virus types I and II using panels of sera from Sweden and West Africa. Transfusion (1999) 0.86
Immune responses to HTLV-I(ACH) during acute infection of pig-tailed macaques. AIDS Res Hum Retroviruses (2004) 0.85
The humoral immune response of NIH Swiss and SWR/J mice to vaccination with formalinized AKR or Gross murine leukemia virus. Proc Natl Acad Sci U S A (1977) 0.82
Evaluation of a new, fully automated immunoassay for detection of HTLV-I and HTLV-II antibodies. J Med Virol (2008) 0.79
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Retracted Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science (2009) 10.76
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog (2006) 10.08
Activation of the interferon system by short-interfering RNAs. Nat Cell Biol (2003) 8.63
Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov (2007) 6.33
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci U S A (2007) 4.77
Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature (2007) 4.13
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet (2002) 3.87
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol (2013) 3.41
The perils of pathogen discovery: origin of a novel parvovirus-like hybrid genome traced to nucleic acid extraction spin columns. J Virol (2013) 3.37
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol (2009) 3.24
PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol (2006) 3.13
Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol (2002) 3.06
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer (2008) 2.85
Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys (2004) 2.84
Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. J Virol (2008) 2.83
Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol (2008) 2.83
Ancient co-speciation of simian foamy viruses and primates. Nature (2005) 2.71
Laparoscopic radical nephrectomy: incorporating advantages of hand assisted and standard laparoscopy. J Urol (2003) 2.61
General protein diffusion barriers create compartments within bacterial cells. Cell (2012) 2.48
The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. Proc Natl Acad Sci U S A (2012) 2.45
IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest (2006) 2.41
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys (2007) 2.41
Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J Virol (2002) 2.37
Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer (2002) 2.33
Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol (2007) 2.31
Surgical resection of renal cell carcinoma after targeted therapy. J Urol (2009) 2.29
Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol (2012) 2.24
Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. J Virol (2007) 2.21
Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J Clin Microbiol (2009) 2.18
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol (2002) 2.13
Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment. Urology (2011) 2.12
Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. Urology (2013) 2.08
Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria. Urology (2011) 2.07
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology (2010) 2.04
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol (2008) 2.03
Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer (2009) 2.02
Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy. Eur Urol (2008) 2.02
Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol (2004) 2.01
Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys (2002) 2.01
Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J Clin Microbiol (2004) 2.01
Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer. J Virol (2009) 2.00
A metagenomic analysis of pandemic influenza A (2009 H1N1) infection in patients from North America. PLoS One (2010) 1.99
A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol (2009) 1.97
Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates. Cancer Res (2003) 1.95
The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome. Nat Rev Urol (2010) 1.94
Variations among experienced surgeons in cancer control after open radical prostatectomy. J Urol (2010) 1.93
Growth control by intracellular tension and extracellular stiffness. Trends Cell Biol (2008) 1.93
RNase L plays a role in the antiviral response to West Nile virus. J Virol (2006) 1.92
No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected. Science (2011) 1.90
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med (2002) 1.88
Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol (2008) 1.86
Thermodynamically modulated partially double-stranded linear DNA probe design for homogeneous real-time PCR. Nucleic Acids Res (2007) 1.82
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J Virol Methods (2004) 1.82
Functional replacement of the carboxy-terminal two-thirds of the influenza A virus NS1 protein with short heterologous dimerization domains. J Virol (2002) 1.81
Use of a multifaceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study. J Infect Dis (2012) 1.78
Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis (2011) 1.76
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology (2006) 1.75
Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J Clin Microbiol (2005) 1.75
New insights into the role of RNase L in innate immunity. J Interferon Cytokine Res (2010) 1.73
Is there a standard of care for pathologic stage T3 prostate cancer? J Clin Oncol (2009) 1.73
Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.71
Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology (2008) 1.71
Chemoprevention of prostate cancer. J Urol (2009) 1.70
Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics (2013) 1.70
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst (2014) 1.67
Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol (2002) 1.66
A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy. Int J Radiat Oncol Biol Phys (2004) 1.64